Article
Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - 1 Jul 2018
Peiffer Kai-Henrik, Vermehren Johannes, Kuhnhenn Lisa, Susser Simone, Dietz Julia, Finkelmeier Fabian, Weiler Nina, Welzel Tania, Grammatikos Georgios, Zeuzem Stefan, Sarrazin Christoph
Abstract excerpt
AIM: Different combinations of direct antiviral agents (DAA) lead to high SVR rates in HCV genotype 1 infected patients. However, presence of baseline resistance-associated substitutions (RASs) represents a major risk factor for treatment failure. It is unknown whether choice of treatment based on RASs has the potential to decrease virologic failure rates. METHODS: Population-based sequencing of NS3 and NS5A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.